How it all starts: Initiation of the clotting cascade

Critical Reviews in Biochemistry and Molecular Biology

Volumn 50, Issue 4, 2015, Pages 326-336

  Smith, Stephanie A ^a   Travers, Richard J ^a   Morrissey, James H ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Blood coagulation; contact pathway; factor VII; factor XII; polyphosphate; tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; COMPLEMENT COMPONENT C1S INHIBITOR; ENZYME PRECURSOR; FIBRIN; FIBRINOGEN; GLYCOSAMINOGLYCAN; KALLIKREIN; KININOGEN; POLYPHOSPHATE; THROMBIN; THROMBOPLASTIN;

ATHEROSCLEROTIC PLAQUE; BLEEDING; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; DISSEMINATED INTRAVASCULAR CLOTTING; ENZYME ACTIVITY; EXTRACORPOREAL OXYGENATION; FIBRIN POLYMERIZATION; HEART INFARCTION; HEMODIALYSIS; HEMOSTASIS; HUMAN; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; REGULATORY MECHANISM; REVIEW; SEPSIS; THROMBOCYTE ACTIVATION; THROMBOSIS; ANIMAL; BIOLOGICAL MODEL; BLOOD; METABOLISM;

ANIMALS; BLOOD COAGULATION; HEMOSTASIS; HUMANS; MODELS, BIOLOGICAL; PLATELET ACTIVATION; PROTEOLYSIS; THROMBOPLASTIN; THROMBOSIS;

EID: 84942256481     PISSN: 10409238     EISSN: 15497798     Source Type: Journal    
DOI: 10.3109/10409238.2015.1050550     Document Type: Review

References (172)

1. Ahamed J, Versteeg HH, Kerver M, et al. (2006). Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci USA 103:13932-7.
2. Ault-Riché D, Fraley CD, Tzeng CM, Kornberg A. (1998). Novel assay reveals multiple pathways regulating stress-induced accumulations of inorganic polyphosphate in Escherichia coli. J Bacteriol 180:1841-7.
3. Bach R, Rifkin DB. (1990). Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. Proc Natl Acad Sci USA 87: 6995-9.
4. Bach RR, Moldow CF. (1997). Mechanism of tissue factor activation on HL-60 cells. Blood 89:3270-6.
5. Bajaj MS, Kuppuswamy MN, Manepalli AN, Bajaj SP. (1999). Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. Thromb Haemost 82:1047-52.
6. Balleisen L, Schulte H, Assmann G, et al. (1987). Coagulation factors and the progress of coronary heart disease. Lancet 2:461.
7. Bergamaschini L, Donarini C, Foddi C, et al. (2001). The region 1-11 of Alzheimer amyloid-beta is critical for activation of contact-kinin system. Neurobiol Aging 22:63-9.
8. Bergamaschini L, Parnetti L, Pareyson D, et al. (1998). Activation of the contact system in cerebrospinal fluid of patients with Alzheimer disease. Alzheimer Dis Assoc Disord 12:102-8.
9. Bogdanov VY, Balasubramanian V, Hathcock J, et al. (2003). Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 9:458-62.
10. 2+, phospholipids and tissue-factor apoprotein to the activation of human bloodcoagulation factor X by activated factor VII. Biochem J 265:327-36.
11. Broadhurst P, Kelleher C, Hughes L, et al. (1990). Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis 85:169-73.
12. Brown MR, Kornberg A. (2004). Inorganic polyphosphate in the origin and survival of species. Proc Natl Acad Sci USA 101:16085-7.
13. Broze Jr GJ, Majerus PW. (1980). Purification and properties of human coagulation factor VII. J Biol Chem 255:1242-7.
14. Brunnée T, Reddigari SR, Shibayama Y, et al. (1997). Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions. Clin Exp Allergy 27:653-63.
15. Büller HR, Bethune C, Bhanot S, et al. (2015). Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 372:232-40.
16. Camera M, Brambilla M, Facchinetti L, et al. (2012). Tissue factor and atherosclerosis: not only vessel wall-derived TF, but also plateletassociated TF. Thromb Res 129:279-84.
17. Camerer E, Kolsto AB, Prydz H. (1996). Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 81:1-41.
18. Carvalho De Sousa J, Azevedo J, Soria C, et al. (1988). Factor VII hyperactivity in acute myocardial thrombosis: a relation to the coagulation activation. Thromb Res 51:165-73.
19. Chan JCY, Rosen ED, Carmeliet P, et al. (1997). Factor VII deficiency rescues the intrauterine lethality of tissue factor pathway inhibitor deficient mice. Blood 90:1775.
20. Chang JY, Monroe DM, Oliver JA, Roberts HR. (1999). TFPIbeta, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene. Thromb Haemost 81:45-9.
21. Choi SH, Collins JN, Smith SA, et al. (2010). Phosphoramidate end labeling of inorganic polyphosphates: facile manipulation of polyphosphate for investigating and modulating its biological activities. Biochemistry 49:9935-41.
22. Chouhan VD, Comerota AJ, Sun L, et al. (1999). Inhibition of tissue factor pathway during intermittent pneumatic compression: a possible mechanism for antithrombotic effect. Arterioscler Thromb Vasc Biol 19:2812-17.
23. Colhoun HM, Zito F, Norman Chan N, et al. (2002). Activated factor XII levels and factor XII 46C>T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. Atherosclerosis 163:363-9.
24. Cooper JA, Miller GJ, Bauer KA, et al. (2000). Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 102:2816-22.
25. Cortellaro M, Boschetti C, Cofrancesco E, et al. (1992). The PLAT study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. Arterioscler Thromb 12:1063-70.
26. Crosby JR, Marzec U, Revenko AS, et al. (2013). Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol 33:1670-8.
27. Danielsen R, Onundarson PT, Thors H, et al. (1998). Activated and total coagulation factor VII, and fibrinogen in coronary artery disease. Scand Cardiovasc J 32:87-95.
28. Docampo R, Moreno SN. (2011). Acidocalcisomes. Cell Calcium 50: 113-9.
29. Doggen CJ, Rosendaal FR, Meijers JC. (2006). Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood 108: 4045-51.
30. Drake TA, Cheng J, Chang A, Taylor Jr FB. (1993). Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis. Am J Pathol 142:1458-70.
31. Drake TA, Morrissey JH, Edgington TS. (1989a). Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 134:1087-97.
32. Drake TA, Ruf W, Morrissey JH, Edgington TS. (1989b). Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factorproducing neoplastic cell line. J Cell Biol 109:389-95.
33. Fair DS. (1983). Quantitation of factor VII in the plasma of normal and warfarin-treated individuals by radioimmunoassay. Blood 62:784-91.
34. Fleck RA, Rao LVM, Rapaport SI, Varki N. (1990). Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res 59:421-37.
35. Folsom AR, Wu KK, Shahar E, Davis CE. (1993). Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb 13:1829-36.
36. Forrester JS, Litvack F, Grundfest W, Hickey A. (1987). A perspective of coronary disease seen through the arteries of living man. Circulation 75:505-13.
37. Gailani D, Renné T. (2007). Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 27:2507-13.
38. Geczy CL. (1994). Cellular mechanisms for the activation of blood coagulation. Int Rev Cytol 152:49-108.
39. Geddings JE, Mackman N. (2014). New players in haemostasis and thrombosis. Thromb Haemost 111:570-4.
40. Giesen PLA, Rauch U, Bohrmann B, et al. (1999). Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 96: 2311-15.
41. Girard TJ, Warren LA, Novotny WF, et al. (1989). Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338:518-20.
42. Grabowski EF, Zuckerman DB, Nemerson Y. (1993). The functional expression of tissue factor by fibroblasts and endothelial cells under flow conditions. Blood 81:3265-70.
43. Grant PJ. (2003). The genetics of atherothrombotic disorders: a clinician's view. J Thromb Haemost 1:1381-90.
44. Griffin JH, Cochrane CG. (1976). Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci USA 73:2554-8.
45. Grundt H, Nilsen DW, Hetland O, et al. (2004). Activated factor 12 (FXIIa) predicts recurrent coronary events after an acute myocardial infarction. Am Heart J 147:260-6.
46. Hackeng TM, Sere KM, Tans G, Rosing J. (2006). Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 103:3106-11.
47. Hansen JB, Huseby NE, Sandset PM, et al. (1994). Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 14: 223-9.
48. Hansen JB, Svensson B, Olsen R, et al. (2000). Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost 83:937-43.
49. Herwald H, Mörgelin M, Olsén A, et al. (1998). Activation of the contact-phase system on bacterial surfaces - a clue to serious complications in infectious diseases. Nat Med 4:298-302.
50. Hoffman C, Shah A, Sodums M, Hultin MB. (1988). Factor VII activity state in coronary artery disease. J Lab Clin Med 111:475-81.
51. Hoffman CJ, Miller RH, Lawson WE, Hultin MB. (1989). Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease. J Am Coll Cardiol 14:941-6.
52. Hojima Y, Cochrane CG, Wiggins RC, et al. (1984). In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood 63:1453-9.
53. Huang ZF, Higuchi D, Lasky N, Broze Jr GJ. (1997). Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 90:944-51.
54. Huang ZF, Wun TC, Broze Jr GJ. (1993). Kinetics of factor Xa inhibition by tissue factor pathway inhibitor. J Biol Chem 268: 26950-5.
55. Hultin MB. (1991). Fibrinogen and factor VII as risk factors in vascular disease. Prog Hemost Thromb 10:215-41.
56. Ichikawa K, Nakagawa K, Hirano K, Sueishi K. (1996). The localization of tissue factor and apolipoprotein(a) in atherosclerotic lesions of the human aorta and their relation to fibrinogen-fibrin transition. Pathol Res Pract 192:224-32.
57. Jain S, Pitoc GA, Holl EK, et al. (2012). Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proc Natl Acad Sci USA 109: 12938-43.
58. Joseph K, Ghebrehiwet B, Kaplan AP. (2001). Activation of the kininforming cascade on the surface of endothelial cells. Biol Chem 382: 71-5.
59. Kalaria VG, Zareba W, Moss AJ, et al. (2000). Gender-related differences in thrombogenic factors predicting recurrent cardiac events in patients after acute myocardial infarction. The THROMBO Investigators. Am J Cardiol 85:1401-8.
60. Kannemeier C, Shibamiya A, Nakazawa F, et al. (2007). Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA 104:6388-93.
61. Kaplan AP, Ghebrehiwet B. (2010). The plasma bradykinin-forming pathways and its interrelationships with complement. Mol Immunol 47:2161-9.
62. Kario K, Matsuo T, Matsuo M, et al. (1995). Marked increase of activated factor VII in uremic patients. Thromb Haemost 73: 763-7.
63. Kario K, Matsuo T, Sakata T, Miyata T. (1994). Factor VII hyperactivity and ischaemic heart disease. Lancet 343:233.
64. Kario K, Sakata T, Matsuo T, Miyata T. (1993). Factor VII in noninsulin-dependent diabetic patients with microalbuminuria. Lancet 342:1552.
65. Karlsrud TS, Buo L, Aasen AO, Johansen HT. (1996a). Bradykinin release from high molecular weight kininogen in surgical ICU patients. Immunopharmacology 33:365-8.
66. Karlsrud TS, Buo L, Aasen AO, Johansen HT. (1996b). Cleavage of plasma high molecular weight kininogen in surgical ICU patients. Intensive Care Med 22:760-5.
67. Kaufman N, Page JD, Pixley RA, et al. (1991). Alpha 2-macroglobulinkallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood 77:2660-7.
68. Kishimoto TK, Viswanathan K, Ganguly T, et al. (2008). Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 358:2457-67.
69. Kisiel W, Davie EW. (1975). Isolation and characterization of bovine factor VII. Biochemistry 14:4928-34.
70. Kisiel W, Fujikawa K, Davie EW. (1977). Activation of bovine factor VII (proconvertin) by factor XIIa (activated Hageman factor). Biochemistry 16:4189-94.
71. Kleinschnitz C, Stoll G, Bendszus M, et al. (2006). Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 203: 513-18.
72. Komiyama Y, Pedersen AH, Kisiel W. (1990). Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. Biochemistry 29:9418-25.
73. Kondo S, Kisiel W. (1987). Regulation of factor VIIa activity in plasma: evidence that antithrombin III is the sole plasma protease inhibitor of human factor VIIa. Thromb Res 46:325-35.
74. Kornberg A, Rao NN, Ault-Riché D. (1999). Inorganic polyphosphate: a molecule of many functions. Annu Rev Biochem 68:89-125.
75. Koster T, Rosendaal FR, Reitsma PH, et al. (1994). Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - the Leiden Thrombophilia Study (LETS). Thromb Haemost 71:719-22.
76. Kumble KD, Kornberg A. (1995). Inorganic polyphosphate in mammalian cells and tissues. J Biol Chem 270:5818-22.
77. Larsson M, Rayzman V, Nolte MW, et al. (2014). A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 6: 222ra17.
78. Lawson JH, Butenas S, Ribarik N, Mann KG. (1993). Complexdependent inhibition of factor VIIa by antithrombin III and heparin. J Biol Chem 268:767-70.
79. Lefevre M, Kris-Etherton PM, Zhao G, Tracy RP. (2004). Dietary fatty acids, hemostasis, and cardiovascular disease risk. J Am Diet Assoc 104:410-19.
80. Lupu C, Lupu F, Dennehy U, et al. (1995). Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol 15:2055-62.
81. Lupu C, Poulsen E, Roquefeuil S, et al. (1999). Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 19:2251-62.
82. Maas C, Govers-Riemslag JW, Bouma B, et al. (2008). Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 118:3208-18.
83. Mandle Jr R, Kaplan AP. (1977). Hageman factor substrates. Human plasma prekallikrein: mechanism of activation by Hageman factor and participation in Hageman factor-dependent fibrinolysis. J Biol Chem 252:6097-104.
84. Marmur JD, Thiruvikraman SV, Fyfe BS, et al. (1996). Identification of active tissue factor in human coronary atheroma. Circulation 94: 1226-32.
85. Maroney SA, Haberichter SL, Friese P, et al. (2007). Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood 109:1931-7.
86. Martinod K, Wagner DD. (2014). Thrombosis: tangled up in NETs. Blood 123:2768-76.
87. Masys DR, Bajaj SP, Rapaport SI. (1982). Activation of human factor VII by activated factors IX and X. Blood 60:1143-50.
88. Maynard JR, Dreyer BE, Stemerman MB, Pitlick FA. (1977). Tissuefactor coagulant activity of cultured human endothelial and smooth muscle cells and fibroblasts. Blood 50:387-96.
89. Meade TW, Mellows S, Brozovic M, et al. (1986). Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart study. Lancet 2:533-7.
90. Merlo C, Wuillemin WA, Redondo M, et al. (2002). Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. Atherosclerosis 161:261-7.
91. Miller GJ. (1998). Postprandial lipaemia and haemostatic factors. Atherosclerosis 141:S47-51.
92. Miller GJ, Martin JC, Mitropoulos KA, et al. (1996). Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency. Blood 87:4187-96.
93. Moor E, Silveira A, Van't Hooft F, et al. (1995). Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vasc Biol 15:655-64.
94. Moosbauer C, Morgenstern E, Cuvelier SL, et al. (2007). Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood 109:995-1002.
95. Moreno-Sanchez D, Hernandez-Ruiz L, Ruiz FA, Docampo R. (2012). Polyphosphate is a novel pro-inflammatory regulator of mast cells and is located in acidocalcisomes. J Biol Chem 287: 28435-44.
96. Morrissey JH, Broze Jr GJ. (2013). Tissue factor and the initiation and regulation (TFPI) of coagulation. In: Marder VJ, Aird WC, Bennett JS, et al., eds. Hemostasis and thrombosis: basic principles and clinical practice. 6th ed. Philadelphia: Lippincott Williams & Wilkins.
97. Morrissey JH, Fakhrai H, Edgington TS. (1987). Molecular cloning of the cDNA for tissue factor, the cellular receptor for the initiation of the coagulation protease cascade. Cell 50:129-35.
98. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. (1993). Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 81:734-44.
99. Mulder AB, Smit JW, Bom VJ, et al. (1996). Association of smooth muscle cell tissue factor with caveolae. Blood 88:1306-13.
100. Müller F, Gailani D, Renné T. (2011). Factor XI and XII as antithrombotic targets. Curr Opin Hematol 18:349-55.
101. Müller F, Mutch NJ, Schenk WA, et al. (2009). Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 139: 1143-56.
102. Müller F, Renné T. (2008). Novel roles for factor XII-driven plasma contact activation system. Curr Opin Hematol 15:516-21.
103. Naumnik B, Rydzewska-Rosolowska A, Mysliwiec M. (2011). Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: a prospective crossover randomized study. Clin Appl Thromb Hemost 17:480-6.
104. Nemerson Y, Gentry R. (1986). An ordered addition, essential activation model of the tissue factor pathway of coagulation: evidence for a conformational cage. Biochemistry 25:4020-33.
105. Nemerson Y, Repke D. (1985). Tissue factor accelerates the activation of coagulation factor VII: the role of a bifunctional coagulation cofactor. Thromb Res 40:351-8.
106. Neuenschwander PF, Fiore MM, Morrissey JH. (1993). Factor VII autoactivation proceeds via interaction of distinct protease-cofactor and zymogen-cofactor complexes: implications of a two-dimensional enzyme kinetic mechanism. J Biol Chem 268:21489-92.
107. Neuenschwander PF, Morrissey JH. (1994). Roles of the membraneinteractive regions of factor VIIa and tissue factor: the factor VIIa Gla domain is dispensable for binding to tissue factor but important for activation of factor X. J Biol Chem 269:8007-13.
108. Nickel KF, Renné T. (2012). Crosstalk of the plasma contact system with bacteria. Thromb Res 130:S78-83.
109. Noga O, Brunnée T, Schäper C, Kunkel G. (1999). Heparin, derived from the mast cells of human lungs is responsible for the generation of kinins in allergic reactions due to the activation of the contact system. Int Arch Allergy Immunol 120:310-16.
110. Nossel HL. (1967). Differential consumption of coagulation factors resulting from activation of the extrinsic (tissue thromboplastin) or the intrinsic (foreign surface contact) pathways. Blood 29: 331-40.
111. Novotny WF, Brown SG, Miletich JP, et al. (1991). Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 78:387-93.
112. Novotny WF, Girard TJ, Miletich JP, Broze Jr GJ. (1988). Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 72: 2020-5.
113. Novotny WF, Girard TJ, Miletich JP, Broze Jr GJ. (1989). Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 264:18832-7.
114. Orlando M, Leri O, Macioce G, et al. (1987). Factor VII in subjects at risk for thromboembolism: activation or increased synthesis? Haemostasis 17:340-3.
115. Østerud B. (2012). Tissue factor/TFPI and blood cells. Thromb Res 129: 274-8.
116. Paborsky LR, Caras IW, Fisher KL, Gorman CM. (1991). Lipid association, but not the transmembrane domain, is required for tissue factor activity: substitution of the transmembrane domain with a phosphatidylinositol anchor. J Biol Chem 266:21911-16.
117. Pedersen B, Holscher T, Sato Y, et al. (2005). A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice. Blood 105: 2777-82.
118. Piro O, Broze Jr GJ. (2004). Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding. Circulation 110:3567-72.
119. Piro O, Broze Jr GJ. (2005). Comparison of cell-surface TFPIalpha and beta. J Thromb Haemost 3:2677-83.
120. 32P]orthophosphate into long chains of inorganic polyphosphate within lysosomes of human fibroblasts. J Biol Chem 267:3626-31.
121. Radcliffe R, Nemerson Y. (1975). Activation and control of factor VII by activated factor X and thrombin: isolation and characterization of a single chain form of factor VII. J Biol Chem 250:388-95.
122. Rao LV, Rapaport SI. (1988). Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 85:6687-91.
123. Rao LV, Rapaport SI, Hoang AD. (1993). Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa. Blood 81:2600-7.
124. Renné T. (2013). The factor XII-driven plasma contact system. In: Marder VJ, Aird WC, Bennett JS, et al., eds. Hemostasis and thrombosis: basic principles and clinical practice. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 242-53.
125. Renné T, Pozgajová M, Grüner S, et al. (2005). Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 202: 271-81.
126. Renné T, Schmaier AH, Nickel KF, et al. (2012). In vivo roles of factor XII. Blood 120:4296-303.
127. Römisch J. (2002). Factor VII activating protease (FSAP): a novel protease in hemostasis. Biol Chem 383:1119-24.
128. Ruddock V, Meade TW. (1994). Factor-VII activity and ischaemic heart disease: fatal and non-fatal events. Q J Med 87:403-6.
129. Ruiz FA, Lea CR, Oldfield E, Docampo R. (2004). Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem 279: 44250-7.
130. Sabatier F, Roux V, Anfosso F, et al. (2002). Interaction of endothelial microparticles with monocytic cells in vitro induces tissue factordependent procoagulant activity. Blood 99:3962-70.
131. Sala-Cunill A, Bjorkqvist J, Senter R, et al. (2015). Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. J Allergy Clin Immunol 135:1031-43.e6.
132. Salomon O, Steinberg DM, Koren-Morag N, et al. (2008). Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 111:4113-17.
133. Sandset PM, Abildgaard U, Larsen ML. (1988). Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 50: 803-13.
134. Sandset PM, Lund H, Norseth J, et al. (1991). Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb 11:138-45.
135. Scarpati EM, Wen D, Broze Jr GJ, et al. (1987). Human tissue factor: cDNA sequence and chromosome localization of the gene. Biochemistry 26:5234-8.
136. Schmaier AH. (2008). Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system. Int Immunopharmacol 8: 161-5.
137. Schmaier AH, Mccrae KR. (2007). The plasma kallikrein-kinin system: its evolution from contact activation. J Thromb Haemost 5: 2323-9.
138. Seligsohn U, Kasper CK, Østerud B, Rapaport SI. (1979a). Activated factor VII: presence in factor IX concentrates and persistence in the circulation after infusion. Blood 53:828-37.
139. Seligsohn U, Østerud B, Brown SF, et al. (1979b). Activation of human factor VII in plasma and in purified systems: roles of activated factor IX, kallikrein, and activated factor XII. J Clin Invest 64: 1056-65.
140. Sevinsky JR, Rao LV, Ruf W. (1996). Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 133:293-304.
141. Shibayama Y, Joseph K, Nakazawa Y, et al. (1999). Zinc-dependent activation of the plasma kinin-forming cascade by aggregated beta amyloid protein. Clin Immunol 90:89-99.
142. r of the activating polyanion. Biochem J 248: 715-20.
143. Silverberg M, Dunn JT, Garen L, Kaplan AP. (1980). Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate. J Biol Chem 255:7281-6.
144. Smith SA, Choi SH, Collins JN, et al. (2012). Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation. Blood 120:5103-10.
145. Smith SA, Choi SH, Davis-Harrison R, et al. (2010). Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood 116:4353-9.
146. Smith SA, Mutch NJ, Baskar D, et al. (2006). Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 103: 903-8.
147. Sosef MN, Bosch JG, Van Oostayen J, et al. (1994). Relation of plasma coagulation factor VII and fibrinogen to carotid artery intima-media thickness. Thromb Haemost 72:250-4.
148. Spicer EK, Horton R, Bloem L, et al. (1987). Isolation of cDNA clones coding for human tissue factor: primary structure of the protein and cDNA. Proc Natl Acad Sci USA 84:5148-52.
149. Suzuki T, Yamauchi K, Matsushita T, et al. (1991). Elevation of factor VII activity and mass in coronary artery disease of varying severity. Clin Cardiol 14:731-6.
150. Tankersley DL, Finlayson JS. (1984). Kinetics of activation and autoactivation of human factor XII. Biochemistry 23:273-9.
151. Tavoosi N, Smith SA, Davis-Harrison RL, Morrissey JH. (2013). Factor VII and protein C are phosphatidic acid-binding proteins. Biochemistry 52:5545-52.
152. 100 Escherichia coli in the baboon. Haemostasis 26:83-91.
153. Taylor Jr FB, Chang A, Ruf W, et al. (1991). Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 33:127-34.
154. Thaler J, Ay C, Mackman N, et al. (2012). Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost 10:1363-70.
155. Thiruvikraman SV, Guha A, Roboz J, et al. (1996). In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X. Lab Invest 75:451-61.
156. Tipping PG, Malliaros J, Holdsworth SR. (1989). Procoagulant activity expression by macrophages from atheromatous vascular plaques. Atherosclerosis 79:237-43.
157. Todoroki H, Higure A, Okamoto K, et al. (1998). Possible role of platelet-activating factor in the in vivo expression of tissue factor in neutrophils. J Surg Res 80:149-55.
158. Travers RJ, Shenoi RA, Kalathottukaren MT, et al. (2014). Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood 124:3183-90.
159. Tsujioka H, Suehiro A, Kakishita E. (1999). Activation of coagulation factor VII by tissue-type plasminogen activator. Am J Hematol 61: 34-9.
160. Vaziri ND, Kennedy SC, Kennedy D, Gonzales E. (1992). Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris. Am J Med 93:651-7.
161. Versteeg HH, Ruf W. (2011). Thiol pathways in the regulation of tissue factor prothrombotic activity. Curr Opin Hematol 18:343-8.
162. Walenga JM, Jeske WP, Samama MM, et al. (2002). Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs 11:397-407.
163. Walford HH, Zuraw BL. (2014). Current update on cellular and molecular mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol 112:413-18.
164. Wesselschmidt R, Likert K, Huang Z, et al. (1993). Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin. Blood Coagul Fibrinolysis 4:661-9.
165. Westmuckett AD, Lupu C, Roquefeuil S, et al. (2000). Fluid flow induces upregulation of synthesis and release of tissue factor pathway inhibitor in vitro. Arterioscler Thromb Vasc Biol 20: 2474-82.
166. Wilcox JN, Smith KM, Schwartz SM, Gordon D. (1989). Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 86:2839-43.
167. Wildgoose P, Nemerson Y, Hansen LL, et al. (1992). Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood 80: 25-8.
168. Yamamoto M, Nakagaki T, Kisiel W. (1992). Tissue factor-dependent autoactivation of human blood coagulation factor VII. J Biol Chem 267:19089-94.
169. Yan SF, Mackman N, Kisiel W, et al. (1999). Hypoxia/hypoxemiainduced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. Arterioscler Thromb Vasc Biol 19: 2029-35.
170. Yau JW, Liao P, Fredenburgh JC, et al. (2014). Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 123:2102-7.
171. Zeerleder S. (2011). C1-inhibitor: more than a serine protease inhibitor. Semin Thromb Hemost 37:362-74.
172. Zhang J, Piro O, Lu L, Broze Jr GJ. (2003). Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation 108:623-7.